PMID- 25127747
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20191210
IS  - 1578-1879 (Electronic)
IS  - 0214-9168 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Mar-Apr
TI  - [Impact of plasma pro-B-type natriuretic peptide amino-terminal and galectin-3 
      levels on the predictive capacity of the LIPID Clinical Risk Scale in stable 
      coronary disease].
PG  - 57-63
LID - S0214-9168(14)00096-5 [pii]
LID - 10.1016/j.arteri.2014.06.003 [doi]
AB  - INTRODUCTION: At present, there is no tool validated by scientific societies for 
      risk stratification of patients with stable coronary artery disease (SCAD). It 
      has been shown that plasma levels of monocyte chemoattractant protein-1 (MCP-1), 
      galectin-3 and pro-B-type natriuretic peptide amino-terminal (NT-proBNP) have 
      prognostic value in this population. OBJECTIVE: To analyze the prognostic value 
      of a clinical risk scale published in Long-term Intervention with Pravastatin in 
      Ischemic Disease (LIPID) study and determining its predictive capacity when 
      combined with plasma levels of MCP-1, galectin-3 and NT-proBNP in patients with 
      SCAD. METHODS AND RESULTS: A total of 706 patients with SCAD and a history of 
      acute coronary syndrome (ACS) were analyzed over a follow up period of 2.2 +/- 0.99 
      years. The primary endpoint was the occurrence of an ischemic event (any SCA, 
      stroke or transient ischemic attack), heart failure, or death. A clinical risk 
      scale derived from the LIPID study significantly predicted the development of the 
      primary endpoint, with an area under the ROC curve (Receiver Operating 
      Characteristic) of 0.642 (0.579 to 0.705); P<0.001. A composite score was 
      developed by adding the scores of the LIPID and scale decile levels of MCP -1, 
      galectin -3 and NT-proBNP. The predictive value improved with an area under the 
      curve of 0.744 (0.684 to 0.805); P<0.001 (P=0.022 for comparison). A score 
      greater than 21.5 had a sensitivity of 74% and a specificity of 61% for the 
      development of the primary endpoint (P<0.001, log -rank test). CONCLUSION: Plasma 
      levels of MCP-1, galectin -3 and NT-proBNP improve the ability of the LIPID 
      clinical scale to predict the prognosis of patients with SCAD.
CI  - Copyright (c) 2014 Sociedad Espanola de Arteriosclerosis. Published by Elsevier 
      Espana. All rights reserved.
FAU - Higueras, Javier
AU  - Higueras J
AD  - Servicio de Cardiologia, Hospital Clinico Universitario San Carlos, Madrid, 
      Espana; Universidad Complutense, Madrid, Espana.
FAU - Martin-Ventura, Jose Luis
AU  - Martin-Ventura JL
AD  - Universidad Autonoma, Madrid, Espana; Laboratorio de Patologia Vascular, 
      IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Blanco-Colio, Luis
AU  - Blanco-Colio L
AD  - Laboratorio de Patologia Vascular, IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Cristobal, Carmen
AU  - Cristobal C
AD  - Servicio de Cardiologia, Hospital de Fuenlabrada, Fuenlabrada, Madrid, Espana; 
      Universidad Rey Juan Carlos, Alcorcon, Madrid, Espana.
FAU - Tarin, Nieves
AU  - Tarin N
AD  - Servicio de Cardiologia, Hospital Universitario de Mostoles, Mostoles, Madrid, 
      Espana.
FAU - Huelmos, Ana
AU  - Huelmos A
AD  - Servicio de Cardiologia, Hospital Universitario Fundacion Alcorcon, Alcorcon, 
      Madrid, Espana.
FAU - Alonso, Joaquin
AU  - Alonso J
AD  - Servicio de Cardiologia, Hospital de Fuenlabrada, Fuenlabrada, Madrid, Espana; 
      Universidad Rey Juan Carlos, Alcorcon, Madrid, Espana.
FAU - Pello, Ana
AU  - Pello A
AD  - Servicio de Cardiologia, IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Acena, Alvaro
AU  - Acena A
AD  - Servicio de Cardiologia, IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Carda, Rocio
AU  - Carda R
AD  - Servicio de Cardiologia, IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Lorenzo, Oscar
AU  - Lorenzo O
AD  - Universidad Autonoma, Madrid, Espana; Laboratorio de Patologia Vascular, 
      IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Mahillo-Fernandez, Ignacio
AU  - Mahillo-Fernandez I
AD  - Servicio de Medicina Preventiva, IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Asensio, Dolores
AU  - Asensio D
AD  - Laboratorio de bioquimica de la Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Almeida, Pedro
AU  - Almeida P
AD  - Servicio de Cardiologia, IIS-Fundacion Jimenez Diaz, Madrid, Espana.
FAU - Rodriguez-Artalejo, Fernando
AU  - Rodriguez-Artalejo F
AD  - Servicio de Medicina Preventiva y Salud Publica, Escuela de Medicina, Universidad 
      Autonoma, Madrid, Espana.
FAU - Farre, Jeronimo
AU  - Farre J
AD  - Universidad Autonoma, Madrid, Espana; Servicio de Cardiologia, IIS-Fundacion 
      Jimenez Diaz, Madrid, Espana.
FAU - Lopez Bescos, Lorenzo
AU  - Lopez Bescos L
AD  - Universidad Rey Juan Carlos, Alcorcon, Madrid, Espana.
FAU - Egido, Jesus
AU  - Egido J
AD  - Universidad Autonoma, Madrid, Espana; Laboratorio de Patologia Vascular, 
      IIS-Fundacion Jimenez Diaz, Madrid, Espana; CIBERDEM, Madrid, Espana.
FAU - Tunon, Jose
AU  - Tunon J
AD  - Universidad Autonoma, Madrid, Espana; Laboratorio de Patologia Vascular, 
      IIS-Fundacion Jimenez Diaz, Madrid, Espana; Servicio de Cardiologia, 
      IIS-Fundacion Jimenez Diaz, Madrid, Espana. Electronic address: 
      jtunon@secardiologia.es.
LA  - spa
PT  - Journal Article
PT  - Validation Study
TT  - Impacto de los niveles plasmaticos de pro-peptido natriuretico tipo B 
      aminoterminal, proteina quimiotactica de monocitos-1 y galectina3 en la capacidad 
      predictiva de eventos de la escala clinica LIPID en la enfermedad coronaria 
      estable.
DEP - 20140813
PL  - Spain
TA  - Clin Investig Arterioscler
JT  - Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad 
      Espanola de Arteriosclerosis
JID - 9208512
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Galectin 3)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - KXO2KT9N0G (Pravastatin)
SB  - IM
MH  - Aged
MH  - Chemokine CCL2/*blood
MH  - Coronary Artery Disease/blood/drug therapy/*physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Galectin 3/*blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Pravastatin/therapeutic use
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - Enfermedad coronaria estable
OT  - Galectina-3
OT  - Galectine-3
OT  - NT-proBNP
OT  - Pro-peptido natriuretico tipo B aminoterminal
OT  - Stable coronary artery disease
EDAT- 2014/08/17 06:00
MHDA- 2016/11/01 06:00
CRDT- 2014/08/17 06:00
PHST- 2014/05/23 00:00 [received]
PHST- 2014/06/23 00:00 [accepted]
PHST- 2014/08/17 06:00 [entrez]
PHST- 2014/08/17 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - S0214-9168(14)00096-5 [pii]
AID - 10.1016/j.arteri.2014.06.003 [doi]
PST - ppublish
SO  - Clin Investig Arterioscler. 2015 Mar-Apr;27(2):57-63. doi: 
      10.1016/j.arteri.2014.06.003. Epub 2014 Aug 13.